NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
URGN
UroGen Pharma Ltd.
URGN has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
URGN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
URGN's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
URGN PE Valuation
URGN has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 15x next year's earnings.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
URGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
URGN has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over URGN on earnings quality, reporting a profit while its opponent remains loss making.
URGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.79 | — |
| Q3 2026 | -$1.33 | +$2.13 |
| Q2 2026 | -$1.99 | +$1.33 |
| Q1 2026 | -$2.76 | +$0.42 |
| Q4 2025 | -$3.21 | +$0.02 |
| Q3 2025 | -$3.46 | -$0.13 |
| Q2 2025 | -$3.32 | +$0.14 |
| Q1 2025 | -$3.18 | +$0.40 |
| Q4 2024 | -$3.23 | +$0.68 |
URGN is still losing money, but far less than before: $1.33 per share over the past year, against $6.40 at its worst in late 2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over URGN on profitability, with a higher operating margin.
URGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $89M | +224% |
| Q2 2026 | $72.5M | +199% |
| Q1 2026 | $51M | +152% |
| Q4 2025 | $37.8M | +54% |
| Q3 2025 | $27.5M | +9% |
| Q2 2025 | $24.2M | +11% |
| Q1 2025 | $20.3M | +7.8% |
| Q4 2024 | $24.6M | +4.4% |
URGN has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.4% | +109 points |
| Q2 2026 | 0.1% | +171 points |
| Q1 2026 | -40% | +143 points |
| Q4 2025 | -51% | +62 points |
| Q3 2025 | -100% | -30 points |
| Q2 2025 | -171% | -53 points |
| Q1 2025 | -182% | -45 points |
| Q4 2024 | -113% | -51 points |
URGN's operating margin was 9.4% last quarter, up 109 points from the same quarter a year ago, near the top of its range since 2020.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over URGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
URGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$15.3M | +$27.1M |
| Q2 2026 | -$33.1M | +$6.9M |
| Q1 2026 | -$45.4M | -$3.3M |
| Q4 2025 | -$38.3M | -$24.6M |
| Q3 2025 | -$42.4M | -$14.6M |
| Q2 2025 | -$40M | -$16.1M |
| Q1 2025 | -$42.1M | -$10.3M |
| Q4 2024 | -$13.7M | -$682K |
URGN has burned cash in almost every quarter: −$132M over the past year, against −$138M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over URGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
URGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +178K shares |
| 1 year | +5.2% | +2.5M shares |
| 3 years | +115% | +27.1M shares |
| 5 years | +126% | +28.2M shares |
| Available history | +146% | +30M shares |
URGN has 51M diluted shares, up 5.2% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
URGN Net Leverage
URGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
URGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.3 | Neutral |
| Stochastic | 3.5 | Oversold |
URGN's weekly RSI is 36 (neutral) and its Stochastic is 4 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
URGN PE vs Healthcare Sector
URGN has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
URGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.1 | 23% below |
| 20 week MA | $39.2 | 33% below |
| 50 week MA | $29.7 | 11% below |
| 100 week MA | $21.9 | 20% above |
| 200 week MA | $17.7 | 49% above |
URGN has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
URGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.1 | $18.9 | -43% |
| 2021 | $18.9 | $9.49 | -50% |
| 2022 | $9.49 | $8.14 | -14% |
| 2023 | $8.14 | $15.0 | +84% |
| 2024 | $15.0 | $10.8 | -28% |
| 2025 | $10.8 | $23.0 | +114% |
| 2026 YTD | $23.0 | $26.4 | +15% |
URGN has the edge over NVO on returns for 2026, with the stronger performance.